The full English name and drug code of Bimetinib/Bemetinib

The English name of Bimetinib/Bemetinib is "Binimetinib". It is a molecular targeted drug that specifically inhibits MEK1 and MEK2 kinases in the MAPK signaling pathway. It was first developed by the American biopharmaceutical company Array BioPharma and jointly promoted by Novartis. The official trade name is "Mektovi". In the early stages of clinical development, bimetinib was widely used under the code name MEK162, which is also its common identifier in major clinical trial databases. MEK162 represents the 162nd candidate molecule among MEK inhibitor drugs and is one of the important targeted drugs in the field of precision medicine.

Abnormalities in the MEK signaling pathway are widely believed to be closely related to the occurrence and development of various tumors, especially tumor cells carrying activating mutations such as BRAF V600E/K, which are more sensitive to MEK inhibitors. Binimetinib achieves anti-tumor effects by specifically inhibiting the activity of MEK kinase, thereby terminating the cascade activation of downstream ERK signals. This mechanism is different from traditional chemotherapy, allowing it to have higher targeting and lower systemic toxicity.

Binimetinib/MEK162 has also become one of the representative drugs in precision medicine and has been widely studied for use in combination treatment strategies, especially in combination with the BRAF inhibitor canafenib, which has shown positive effects in delaying drug resistance and improving median survival. In addition to melanoma, it is also conducting clinical trials in pancreatic cancer, colorectal cancer, non-small cell lung cancer and other RAS/MAPK active tumors, which is expected to further expand its scope of indications.

Understanding the full English name and R&D code name of the drug not only facilitates access to international information, but also helps patients and doctors obtain synchronized information on a global scale and keep abreast of the latest research progress and market dynamics of the drug. It is especially of practical guidance in the process of cross-border medical treatment and generic drug selection.

Reference materials:https://go.drugbank.com/drugs/DB11967